Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) — Tangible Net Worth Ratio
Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) has a Tangible Net Worth Ratio of 96.9% as of September 2025. This metric is calculated by deducting intangible assets (CN¥35.48 Million) from net assets (CN¥1.15 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore net asset growth rate of Suzhou Zelgen Biopharmaceuticals Co Ltd to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Suzhou Zelgen Biopharmaceuticals Co Ltd Tangible Net Worth Ratio (2016–2024)
This chart shows how Suzhou Zelgen Biopharmaceuticals Co Ltd's Tangible Net Worth Ratio has changed across 9 annual periods from 2016 to 2024. As of September 2025, the ratio stands at 96.9%, reflecting net assets of CN¥1.15 Billion with intangible assets of CN¥35.48 Million CNY. For live market cap and overall valuation, see Suzhou Zelgen Biopharmaceuticals Co Ltd stock valuation.
Annual Tangible Net Worth Ratio for Suzhou Zelgen Biopharmaceuticals Co Ltd (2016–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Suzhou Zelgen Biopharmaceuticals Co Ltd from 2016 to 2024, covering 9 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. Explore how much does Suzhou Zelgen Biopharmaceuticals Co Ltd reinvest in capital to see what proportion of operating cash flow is directed to capital expenditures.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 96.0% | CN¥1.25 Billion | CN¥50.01 Million | CN¥3.00 Billion | ▲ +0.2 pp |
| 2023 | 95.8% | CN¥1.64 Billion | CN¥69.27 Million | CN¥2.89 Billion | ▲ +7.3 pp |
| 2022 | 88.4% | CN¥787.49 Million | CN¥91.03 Million | CN¥1.67 Billion | ▼ -2.3 pp |
| 2021 | 90.7% | CN¥1.25 Billion | CN¥116.29 Million | CN¥1.75 Billion | ▼ -1.6 pp |
| 2020 | 92.3% | CN¥1.69 Billion | CN¥129.51 Million | CN¥1.97 Billion | ▲ +176.5 pp |
| 2019 | -84.1% | CN¥73.75 Million | CN¥135.81 Million | CN¥320.27 Million | ▼ -128.6 pp |
| 2018 | 44.5% | CN¥281.64 Million | CN¥156.43 Million | CN¥454.88 Million | ▼ -38.0 pp |
| 2017 | 82.4% | CN¥73.02 Million | CN¥12.84 Million | CN¥147.63 Million | ▼ -5.6 pp |
| 2016 | 88.0% | CN¥109.44 Million | CN¥13.15 Million | CN¥137.20 Million | — |